VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+10.37%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$950M
AUM Growth
+$950M
(+52%)
Cap. Flow
+$335M
Cap. Flow
% of AUM
35.21%
Top 10 Holdings %
Top 10 Hldgs %
62.17%
Holding
40
New
10
Increased
7
Reduced
3
Closed
3
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$181M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$89.2M |
| 3 |
Taysha Gene Therapies
TSHA
|
$45.6M |
| 4 |
HilleVax
HLVX
|
$27.4M |
| 5 |
Travere Therapeutics
TVTX
|
$23.5M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$74.1M |
| 2 |
GH Research
GHRS
|
$7.77M |
| 3 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
$7.18M |
| 4 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$4.77M |
| 5 |
Black Diamond Therapeutics
BDTX
|
$1.79M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apogee Therapeutics
APGE
$2.17B
| $181M | 19.04% | +8,493,321 | New | +$181M |
|
|
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $89.2M | 9.39% | +4,016,847 | New | +$89.2M |
|
3
Viridian Therapeutics
VRDN
$1.5B
| $47.3M | 4.98% | 3,082,622 | – | – |
|
4
Cogent Biosciences
COGT
$1.69B
| $45.7M | 4.81% | 4,684,167 +35 | +0% | +$341 |
|
|
5
Taysha Gene Therapies
TSHA
$797M
| $45.6M | 4.81% | +14,444,444 | New | +$45.6M |
|
6
Merus
MRUS
$4.98B
| $40.7M | 4.28% | 1,726,214 | – | – |
|
7
Enliven Therapeutics
ELVN
$1.2B
| $40.4M | 4.25% | 2,954,902 +724,775 | +32% | +$9.9M |
|
8
4D Molecular Therapeutics
FDMT
$288M
| $38.2M | 4.02% | 3,000,000 | – | – |
|
9
Pharvaris
PHVS
$1.39B
| $32.6M | 3.44% | 1,563,513 +237,313 | +18% | +$4.95M |
|
10
Cabaletta Bio
CABA
$133M
| $30M | 3.16% | 1,973,253 +2 | +0% | +$30 |
|
11
KalVista Pharmaceuticals
KALV
$678M
| $28.1M | 2.96% | 2,916,667 | – | – |
|
|
12
GH Research
GHRS
$837M
| $27.6M | 2.9% | 2,744,125 -773,000 | -22% | -$7.77M |
|
|
13
HilleVax
HLVX
$105M
| $27.4M | 2.88% | +2,037,313 | New | +$27.4M |
|
14
Savara
SVRA
$567M
| $27.2M | 2.86% | 7,184,865 +833,334 | +13% | +$3.15M |
|
15
Rhythm Pharmaceuticals
RYTM
$6.85B
| $25M | 2.63% | 1,090,000 | – | – |
|
|
AMAM
16
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $23.8M | 2.51% | 2,070,000 -414,960 | -17% | -$4.77M |
|
|
17
Travere Therapeutics
TVTX
$1.56B
| $23.5M | 2.47% | +2,623,677 | New | +$23.5M |
|
18
Dyne Therapeutics
DYN
$1.92B
| $19.5M | 2.05% | 2,173,913 | – | – |
|
19
Celcuity
CELC
$2.17B
| $19.2M | 2.03% | 2,105,386 | – | – |
|
20
Terns Pharmaceuticals
TERN
$609M
| $15.6M | 1.64% | 3,092,273 +119,404 | +4% | +$601K |
|
21
Mersana Therapeutics
MRSN
$36.5M
| $14.4M | 1.51% | +11,328,000 | New | +$14.4M |
|
22
Applied Therapeutics
APLT
$71M
| $14.1M | 1.48% | 5,658,034 | – | – |
|
23
Oric Pharmaceuticals
ORIC
$994M
| $13M | 1.36% | 2,142,856 | – | – |
|
24
Dianthus Therapeutics
DNTH
$759M
| $12.7M | 1.34% | +927,706 | New | +$12.7M |
|
25
Adverum Biotechnologies
ADVM
$64.6M
| $9.86M | 1.04% | 6,573,300 +2,687,054 | +69% | +$4.03M |
|